NHS fast-tracks new targeted drug for rare lung cancer
Patients eligible to receive Takeda’s Exkivity (mobocertinib) have a rare form of lung cancer that cannot be removed by surgery - News - PharmaTimes
Stay updated with breaking news from Nhs . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Patients eligible to receive Takeda’s Exkivity (mobocertinib) have a rare form of lung cancer that cannot be removed by surgery - News - PharmaTimes
Patients with a life-limiting skeletal condition welcome availability of elosulfase alfa on the NHS - News - PharmaTimes
The NHS has not met the 18-week target for people to receive planned treatment in England since February 2016 - News - PharmaTimes
COVID-19 has highlighted another significant widespread problem – the mental health pandemic - News - PharmaTimes
93% of people suspected by GPs to have cancer should be seen by a specialist within two weeks but this has fallen to just 75% - News - PharmaTimes